期刊文献+

1例鼻饲患者华法林疗效不足的病例分析

Insufficient curative effect of warfarin in a patient with nasal feeding:case analysis
原文传递
导出
摘要 通过分析鼻饲患者喂养方式、给药方式以及药物相互作用探讨导致华法林疗效不足的影响因素,确定引起国际标准化比值(international normalized ratio,INR)波动的原因,及时调整合并用药、固定给药方式,调整华法林剂量,加强凝血功能的监测,使患者INR恢复到目标值范围。提示临床药师在参与药物治疗过程中,应结合个体化用药及病例特点分析可能的影响因素,减少不良事件发生率。 By analyzing the way of feeding,dosing method and drug interaction,the factors that decreased the efficacy of warfarin in one patient with nasal feeding were identified,the combined medication and warfarin dose were timely adjusted,drug delivery regimen was fixed,and the monitoring of blood coagulation function was strengthened.Finally the international normalized ratio of the patient was restored to the target for treatment.It is suggested that clinical pharmacists should identify the infuencing factors of drug efficacy considering individualized drug use and patient characteristics to minimize adverse events in the course of drug treatment.
作者 张永辉 郑萍 叶启桦 ZHANG Yong-hui;ZHENG Ping;YE Qi-hua(Department of Pharmacy,the Third People′s Hospital of Yunnan Province,Kunming 650011,China;Department of Pharmacy,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Department of Clinical Pharmacy,Dalang Hospital,Guangdong Donguan 5237702,China)
出处 《临床药物治疗杂志》 2019年第5期90-92,共3页 Clinical Medication Journal
关键词 鼻饲 华法林 国际标准化比值 药物相互作用 nasal feeding warfarin international normalized ratio drug interaction
  • 相关文献

参考文献4

二级参考文献50

  • 1王海鹰,荆志成,李崇剑,王建德,徐希奇,邓可武.肺栓塞患者华法林抵抗现象一例及文献回顾[J].中华心血管病杂志,2004,32(11):1039-1040. 被引量:6
  • 2胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 3钟山,崔征,王东,李建林,翟岩.水蛭注射液抗血栓与抗凝血作用[J].沈阳药科大学学报,2006,23(7):456-458. 被引量:27
  • 4孙惠洁,吴永沛.海藻硫酸多糖的制备及其抗凝血活性的研究进展[J].食品与药品,2007,9(08A):54-56. 被引量:10
  • 5Huo MH,James M.Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients:A review[J].Clin Ther,2009,31(6):1129-41.
  • 6Gilles M,Richard G,Harvey DW,et al.Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention:1-year results from the steeple(safety and efficacy of enoxaparin in percutaneous coronary intervention patients,an international randomized evaluation)trial[J].JACC,2009,11(2):1083-91.
  • 7Tetri S,Hakala J,Juvela S,et al.Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage[J].Thromb Res,2008,123:206-12.
  • 8Gibson CM,Murphy SA,Montalescot G,et al.Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial[J].J Am Coll Cardiol,2007,49:2238-46.
  • 9Ansell J.Long-term anticoagulation:The prospects for alternatives to warfarin[J].Semin Vasc Surg,2005,18:134-8.
  • 10Rashid MA,Parker MJ.Anticoagulation management in hip fracture patients on warfarin[J].Int J Care Injured,2005,36:1311-5.

共引文献641

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部